This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Some say we should hold elections tomorrow, those have no chances of being free and fair." and added "Ultimately what the long term political leadership is going be, it’s going to be up to Venezuelans." During a conference in Saint Kitts and Nevis with other Caribbean nations on 25 February, United States Secretary of State Marco Rubio said that the US recognizes the need for fair, democratic elections in Venezuela, saying "We do believe that a prosperous, free Venezuela who’s governed by a legitimate government who has the interests of their people in mind could also be an extraordinary partner and asset to many of the countries represented here today." Juan Pablo Guanipa, ally of Machado and political prisoner released during a mass political prisoner release in Venezuela in 2026, said for Spanish newspaper El País, that elections are under way and that Chavismo has lost its ability to impose conditions.
==== Escherichia coli cells ==== Photo-methionine can be used to label recombinant proteins in Escherichia coli cells; though methionine in general is a rare amino acid so that means it could only give limited structural data. Nevertheless, photo-methionine was incorporated into Ca2+ regulating protein calmodulin (CaM that was 17-kDa) that has nine methionine's and studied via mass spectrometry (MS). What makes this method different is the use of mineral salts medium instead of DMEM (Dulbecco's Modified Eagle's Limiting Medium) or dialyzed fetal bovine serum for the incorporation into the cells. Using the mineral salt medium allowed the cells to be grown from the beginning in order to eliminate complicated steps with other protocols (incubating the cells in LB medium, followed by washing, and further incubating in the depleted medium), meaning that photo-methionine could be incorporated at the very beginning of the cell growth that had a high yield above 30%. Photo-methionine had shown no damage during the cell growth process and once photo-activated by UV-A light, CaM had nine distinct cross-link sites once MS had determined there was peaks of photo-methionine labeled CaM. Not only can photo-methionine be used for mapping 3D protein structure, studying protein-protein interactions, but now hydrophobic regions in the protein.
== Early life == Geneviève Meurgues was born on 4 February 1931 in Paris, into a family originally from Saint-Germain-de-Modéon. She had sister and brother, Christiane and Bernard. Until 1962, she worked in a medical analysis laboratory while completing her education in chemistry and biochemistry at the Conservatoire national des arts et métiers. She graduated as a chemical engineer in 1967, writing her thesis on the nucleic acids of the fungus Aspergillus niger.
Group specificity occurs when an enzyme will only react with molecules that have specific functional groups, such as aromatic structures, phosphate groups, and methyls. One example is pepsin, an enzyme that is crucial in digestion of foods ingested in our diet, that hydrolyzes peptide bonds in between hydrophobic amino acids, with recognition for aromatic side chains such as phenylalanine, tryptophan, and tyrosine. Another example is hexokinase, an enzyme involved in glycolysis that phosphorylates glucose to produce glucose-6-phosphate. This enzyme exhibits group specificity by allowing multiple hexoses (6 carbon sugars) as its substrate. Glucose is one of the most important substrates in metabolic pathways involving hexokinase due to its role in glycolysis, but is not the only substrate that hexokinase can catalyze a reaction with.
In 1945, Libby moved to the University of Chicago, where he began his work on radiocarbon dating. He published a paper in 1946 in which he proposed that the carbon in living matter might include 14C as well as non-radioactive carbon. Libby and several collaborators proceeded to experiment with methane collected from sewage works in Baltimore, and after isotopically enriching their samples they were able to demonstrate that they contained 14C. By contrast, methane created from petroleum showed no radiocarbon activity because of its age. The results were summarized in a paper in Science in 1947, in which the authors commented that their results implied it would be possible to date materials containing carbon of organic origin. Libby and James Arnold proceeded to test the radiocarbon dating theory by analyzing samples with known ages. For example, two samples taken from the tombs of two Egyptian kings, Zoser and Sneferu, independently dated to 2625 BC ± 75 years, were dated by radiocarbon measurement to an average of 2800 BC ± 250 years. These results were published in Science in December 1949. Within 11 years of their announcement, more than 20 radiocarbon dating laboratories had been set up worldwide. In 1960, Libby was awarded the Nobel Prize in Chemistry for this work.
Sources: en.wikipedia.org
Here P1 and V1 represent the original pressure and volume, respectively, and P2 and V2 represent the second pressure and volume. Boyle's law, Charles's law, and Gay-Lussac's law form the combined gas law. The three gas laws in combination with Avogadro's law can be generalized by the ideal gas law.
=== 1963-1967 === In 1963, the Los Angeles Rams acquired Rosey Grier from the New York Giants to play right defensive tackle. Grier joined Lamar Lundy (right defensive end), and future Hall of Famers Merlin Olsen (left defensive tackle) and Deacon Jones (left defensive end) on the team's starting defensive line. In 1964, the Rams' publicity office began using the "Fearsome Foursome" name to describe the team's defensive line, reportedly following the Chargers example. It was the Rams' Fearsome Foursome, however, that became the standard by which future teams' defensive lines were measured. Hall of Fame linebacker, and one of the NFL's greatest defensive players, Dick Butkus called them "the most dominant line in football history." The Associated Press’s obituary of Jones called the Rams line unblockable at times, and reported descriptions of Jones as the paradigm for all the great defensive ends that followed, an “icon among icons” and the “‘greatest defensive end of modern football’”. Grier missed the 1967 season with a ruptured Achilles tendon (and retired before the 1968 season). In September 1967, the Rams traded three high draft choices, including the Rams No. 1 pick in the 1968 draft, to the Detroit Lions for the Lions' Fearsome Four tackle Roger Brown to replace Grier. Brown joined the Rams' Fearsome Foursome, where he played with Jones, Olsen and Lundy from 1967 to 1969. Brown made the Pro Bowl in 1967 (his sixth consecutive appearance). In 2018, USA Today Sportswriter Jim Reineking rated the 1967 Rams line as the greatest ever.
=== Biosensors === Graphene does not oxidize in air or in biological fluids, making it an attractive material for use as a biosensor. A graphene circuit can be configured as a field effect biosensor by applying biological capture molecules and blocking layers to the graphene, then controlling the voltage difference between the graphene and the liquid that includes the biological test sample. Of the various types of graphene sensors that can be made, biosensors were the first to be available for sale.
Other polypeptides and proteins such as amylin and the β amyloid peptide do not have a simple consensus sequence and are thought to aggregate through the sequence segments enriched with hydrophobic residues, or residues with high propensity to form β-sheet structure. Among the hydrophobic residues, aromatic amino-acids are found to have the highest amyloidogenic propensity. Cross-polymerization (fibrils of one polypeptide sequence causing other fibrils of another sequence to form) is observed in vitro and possibly in vivo. This phenomenon is important, since it would explain interspecies prion propagation and differential rates of prion propagation, as well as a statistical link between Alzheimer's and type 2 diabetes. In general, the more similar the peptide sequence the more efficient cross-polymerization is, though entirely dissimilar sequences can cross-polymerize and highly similar sequences can even be "blockers" that prevent polymerization.
Mahathir follows a disciplined lifestyle. He attributes his longevity and health to self-discipline, a controlled diet, regular reading to keep his mind active, and avoiding overeating, which he believes leads to obesity and related diseases. He has consistently maintained his weight at 62 kg for many years. His hobbies include sailing, horse riding, and carpentry, and he has built a functioning steam train and a boat. An avid reader, his favourite authors are Wilbur Smith and Jeffrey Archer.
Sources: en.wikipedia.org
==== Delivery methods ==== Honokiol is most commonly taken orally. There are a number of supplements available containing honokiol. Magnolia tea made from the bark of the tree is also a common delivery method of honokiol. Both Native American and Japanese medicine use tea gargles to treat toothaches and sore throats. Because honokiol is highly hydrophobic it must be dissolved in a lipid for many delivery methods. In many current animal studies the compound is dissolved in a lipid emollient and delivered through intraperitoneal injection. There is ongoing work developing liposomal emulsions for IV delivery.
=== Valve Corporation v. Activision Blizzard === In April 2009, Valve sued Activision Blizzard, which acquired Sierra Entertainment after a merger with its parent company, Vivendi Universal Games. Activision had allegedly refused to honor the Valve v. Vivendi arbitration agreement. Activision had only paid Valve $1,967,796 of the $2,391,932 award, refusing to pay the remaining $424,136, claiming it had overpaid that sum in the past years.
Cholecystokinin tetrapeptide (CCK-4, tetragastrin, Trp-Met-Asp-Phe-NH2) is a peptide fragment derived from the larger peptide hormone cholecystokinin. Unlike cholecystokin which has a variety of roles in the gastrointestinal system as well as central nervous system effects, CCK-4 acts primarily in the brain as an anxiogenic, although it does retain some GI effects, but not as much as CCK-8 or the full length polypeptide CCK-58. CCK-4 reliably causes severe anxiety symptoms when administered to humans in a dose of as little as 50 μg, and is commonly used in scientific research to induce panic attacks for the purpose of testing new anxiolytic drugs. Since it is a peptide, CCK-4 must be administered by injection, and is rapidly broken down once inside the body so has only a short duration of action, although numerous synthetic analogues with modified properties are known.
=== American === Losses on the U.S. side on the first day were 23 aircraft. The second day's airstrike against the Japanese fleet saw most of the aircraft losses for the U.S.; of the 226 aircraft launched on the strike, 115 returned; 20 were lost to enemy action in the attack, and 80 were lost when they ran out of fuel returning to their carriers and had to ditch into the sea, or crashed attempting to land at night. Spruance's conservative battle plan for TF 58, while sinking just one light carrier, severely weakened the Japanese naval aviation forces by killing most of the remaining trained pilots and destroying their operational reserves of naval aircraft, a blow that effectively shattered the Japanese naval air arm, from which it never recovered. Without the time or resources to build sufficient aircraft and train new pilots, the surviving Japanese carriers were almost useless in an offensive role, a fact the Japanese acknowledged by using them as sacrificial decoys at Leyte Gulf. With the effective crippling of her best striking arm, Japan chose to rely increasingly on land-based kamikaze suicide aircraft in a last-ditch effort to make the war so costly that the U.S. would offer peace terms better than unconditional surrender. Spruance was heavily criticized after the battle by many officers, particularly the aviators, for his decision to fight the battle cautiously rather than exploiting his superior forces and intelligence data with a more aggressive posture.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.